To further verify that SPECC1-415aa regulates the TMZ sensitivity of GBM cells through the downstream EGFR-AKT signaling pathway, recovery experiments were performed by using the EGFR blocker osimertinib. This evidence concerns the gene AKT1 and glioblastoma.